患者合并症对全髋关节置换术的经济负担:高合并症负担与非高合并症负担患者的匹配队列分析
该回顾性匹配队列分析纳入2012至2021年间14,949例择期单侧全髋关节置换术患者,将Charlson合并症指数≥5且美国麻醉医师学会评分3或4分者定义为高合并症负担(HCB),经1:1倾向性匹配后每组957例比较财务与90天结局。HCB组总费用和直接费用均显著更高,而收入无显著差异,导致边际贡献显著降低;HCB组非居家出院比例和90天再入院率均显著更高。作者认为现行报销模式应更好反映HCB患者的经济负担。
要点
- HCB组总费用(P < .001)和直接费用(P < .001)显著高于非HCB组。
- 两组收入无显著差异(P = .083),HCB组边际贡献显著降低(P < .001)。
- HCB组非居家出院比例更高(P < .001),90天再入院率更高(P = .049)。
核心结论
- HCB患者全髋关节置换术费用增加但收入未相应增加,导致边际贡献降低。
- HCB人群非居家出院和再入院率更高,进一步增加经济负担。
- 作者认为应调整现行报销模式以更好反映HCB患者的经济负担并确保所有患者获得诊疗。
研究设计与样本
- 回顾性队列分析,纳入2012至2021年间14,949例择期单侧全髋关节置换术患者。
- 按Charlson合并症指数≥5且美国麻醉医师学会评分3或4分定义为HCB组,其余为非HCB组。
- 基于基线特征进行1:1倾向性匹配,最终匹配分析纳入1,914例(每组957例)。
- 证据等级为III级。
主要发现
- 在11,717例有财务数据的患者中,HCB组1,017例,非HCB组10,700例。
- HCB组总费用(P < .001)和直接费用(P < .001)显著高于非HCB组。
- 两组收入无显著差异(P = .083)。
- HCB组边际贡献显著低于非HCB组(P < .001)。
- HCB组非居家出院比例显著更高(P < .001),90天再入院率显著更高(P = .049)。
关键数值与推荐
- HCB定义为Charlson合并症指数≥5且美国麻醉医师学会评分3或4分。
- 财务比较指标包括收入、费用和边际贡献。
- 短期结局比较包括90天再入院和翻修。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of increased patient comorbidities on the cost-effectiveness of total hip arthroplasty (THAs) is lacking. This study aimed to compare revenue, costs, and short-term (90 days) surgical outcomes between patients who have and do not have a high comorbidity burden (HCB). METHODS: We retrospectively reviewed 14,949 patients who underwent an elective, unilateral THA between 2012 and 2021. Patients were stratified into HCB (Charlson Comorbidity Index ≥ 5 and American Society of Anesthesiology scores of 3 or 4) and non-HCB groups, and were further 1:1 propensity matched based on baseline characteristics. Perioperative data, revenue, costs, and contribution margins (CMs) of the inpatient episode were compared between groups. Also, 90-day readmissions and revisions were compared between groups. Of the 11,717 patients who had available financial data (n = 1,017 HCB, n = 10,700 non-HCB), 1,914 patients were included in the final matched analyses (957 per group). RESULTS: Total (P < .001) and direct (P < .001) costs were significantly higher for HCB patients. Comparable revenue between cohorts (P = .083) resulted in a significantly decreased CM in the HCB patient group (P < .001). The HCB patients were less likely to be discharged home (P < .001) and had significantly higher 90-day readmission rates (P = .049). CONCLUSIONS: Increased THA costs for HCB patients were not matched by increased revenue, resulting in decreased CM. Higher rates of nonhome discharge and readmissions in the HCB population add to the additional financial burden. Adjustments to the current reimbursement models should better account for the increased financial burden of HCB patients undergoing THA and ensure access to care for all patient populations. LEVEL OF EVIDENCE: III.
引用
- Ashkenazi I, Thomas J, Katzman J, et al. The Financial Burden of Patient Comorbidities on Total Hip Arthroplasties-A Matched Cohort Analysis of High Comorbidity Burden and Non-High Comorbidity Burden Patients. J Arthroplasty. 2024. PMID: 38417554. doi:10.1016/j.arth.2024.02.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。